https://doi.org/ 10.33472/AFJBS.6.9.2024.1033-1054

African Journal of Biological Sciences

Journal homepage: http://www.afjbs.com

Research Paper Open Access

Pulmonary Surfactants as Drug Delivery Vehicles Exploiting Endogenous Systems for Therapeutic Intervention

Satyajit Panda [1], Bikramaditya Mukherjee [2], Ritesh Kumar [3], Jashanjit Singh [4], Firoj A. Tamboli [5], Shailee Dewan [6], Vishakha Jaiswal [7], Boi Basanta Kumar Reddy [8]*

1. Assistant Professor Institute of Pharmacy and Technology, Salipur, Cuttack, Odisha- 754202
2. Assistant Professor, Department of Biochemistry, Manipal Tata Medical College, Academy of Higher Education, Manipal , Jamshedpur, Manipal -831017
3. Associate Professor, Anand College of Pharmacy, Sharda University Agra, Uttar Pradesh- 282007
4. Associate Professor, Gurukul Institute of Pharmaceutical Sciences, Badesh Kalan, Khamanon, Fatehgarh Sahib, Punjab - 141801
5. Associate Professor, Department of Pharmacognosy, Bharati Vidyapeeth College of Pharmacy kolhapur, Near chitranagari, Kolhapur -416013
6. Assistant Professor, Government Pharmacy College.Sajong, Rumtek, Gangtok, Sikkim-737135
7. Assistant Professor, Amity Institute of Pharmacy, Amity University, Lucknow, Uttar Pradesh, Sector 125, Noida- 201313
8. Professor, Department of Pharmaceutics, Danteswari college of pharmacy, Borapadar, Raipur Road, Jagdalpur, Chhattisgarh -494221

Corresponding Author: Dr. Boi Basanta Kumar Reddy
Designation and Affiliation: Professor, Department of Pharmaceutics, Danteswari college of pharmacy, Borapadar, Raipur Road, Jagdalpur, Chhattisgarh -494221
Email Id: bbasantareddy1@gmail.com

Article History
Volume 6,Issue 9, 2024
Received:23 Feb 2024
Accepted : 21 Mar 2024
doi: 10.33472/AFJBS.6.9.2024.1033-1054

Abstract:
Pulmonary surfactants, composed of lipids and proteins, play vital roles in lung physiology and mechanics. Exploiting their unique properties, such as their interaction with lung epithelium, surfactants have emerged as promising carriers for drug delivery to the lungs. This review explores the potential of pulmonary surfactants as drug delivery vehicles, focusing on leveraging endogenous systems within the lung for therapeutic intervention. Beginning with an overview of pulmonary surfactants and the importance of drug delivery to the lungs, the review highlights the need for innovative strategies to overcome barriers encountered in traditional pulmonary drug delivery approaches. By harnessing the inherent mechanisms of surfactant uptake and recycling, novel avenues for targeted and sustained drug delivery are elucidated. The objectives of this review encompass synthesizing current knowledge, evaluating preclinical and clinical evidence, and identifying future directions in the field. Through this exploration, the review aims to contribute to the advancement of pulmonary therapeutics and healthcare.

Keywords: pulmonary surfactants, drug delivery, endogenous systems, lung, therapeutics

Introduction

In the realm of pulmonary therapeutics, pulmonary surfactants stand as pivotal entities due to their multifaceted roles in lung physiology and pathology[1]. Comprising a complex mixture of lipids and proteins, pulmonary surfactants serve as the primary interface between the lung epithelium and the surrounding air, facilitating respiratory mechanics and maintaining alveolar integrity[2]. However, beyond their physiological functions, the unique properties of pulmonary surfactants have sparked interest in their potential as carriers for drug delivery to the lungs. The lungs present an attractive target for drug delivery owing to their large surface area, extensive vasculature, and direct access to systemic circulation, offering a route for both local and systemic therapeutic interventions[3]. Yet, conventional approaches to pulmonary drug delivery often encounter formidable barriers, including mucociliary clearance, enzymatic degradation, and limited cellular uptake. To overcome these challenges and enhance the efficacy of pulmonary drug delivery, there arises a compelling need to explore and exploit endogenous systems within the lung[4]. By harnessing the inherent mechanisms and pathways already present in the pulmonary milieu, such as surfactant uptake and recycling, it becomes possible to design innovative strategies for targeted and sustained drug delivery to the lungs. Against this backdrop, this review aims to critically examine the current landscape of pulmonary surfactants as drug delivery vehicles, with a specific focus on exploiting endogenous systems for therapeutic intervention[5]. By elucidating the structural and functional intricacies of pulmonary surfactants, assessing the importance of drug delivery to the lungs, highlighting the need for leveraging endogenous systems, and delineating the objectives of this review, a comprehensive foundation is laid for exploring the potential of pulmonary surfactants in advancing pulmonary therapeutics[6]. This review endeavors to delve into the diverse aspects of pulmonary surfactants as carriers for drug delivery, elucidating their potential in overcoming the hurdles encountered in traditional pulmonary drug delivery approaches[7]. Through an in-depth exploration of the composition, structure, and physiological roles of pulmonary surfactants, the unique attributes that render them promising candidates for drug delivery are unveiled. Furthermore, the critical importance of effective drug delivery to the lungs is underscored, emphasizing the significance of addressing respiratory ailments and systemic diseases with targeted therapies[8]. The discussion then pivots towards the imperative of leveraging endogenous systems within the lung for optimizing drug delivery strategies. By harnessing the natural mechanisms of surfactant uptake, recycling, and interaction with lung epithelial cells, novel avenues for enhancing drug delivery efficiency and therapeutic outcomes emerge[9]. Against this backdrop, the objectives of this review are delineated, encompassing a comprehensive synthesis of current knowledge, identification of key challenges, evaluation of preclinical and clinical evidence, and exploration of future directions and emerging trends in the field. With a firm foundation established, this review sets out on a journey to unravel the intricacies of pulmonary surfactant-mediated drug delivery, paving the way for transformative advancements in pulmonary therapeutics and healthcare[10].



Figure 1: Annotated Diagram of Pulmonary Alveoli and Capillary Beds

Pulmonary Surfactants: Structure and Function

Pulmonary surfactants constitute a complex blend of lipids and proteins that are vital for maintaining the integrity and function of the lungs. Understanding their composition, role in lung physiology, and interaction with lung epithelium is fundamental to appreciating their potential as drug delivery vehicles[11].

A. Composition of Pulmonary Surfactants:

Pulmonary surfactants are composed of a complex mixture of lipids and proteins that work synergistically to maintain the physiological function of the lungs. The primary components of pulmonary surfactants are phospholipids, with dipalmitoylphosphatidylcholine (DPPC) being the most abundant[12]. Other phospholipids, suchas phosphatidylglycerol, phosphatidylethanolamine, and phosphatidylinositol, are also present in smaller quantities. These phospholipids contribute to the surface tension-lowering properties of surfactants, crucial for preventing alveolar collapse during expiration and maintaining lung compliance[13]. Additionally, pulmonary surfactants contain surfactant-associated proteins (SP-A, SP-B, SP-C, and SP-D), each with distinct roles in surfactant function. SP-A and SP-D are hydrophilic proteins involved in innate immune defense and immune regulation within the lungs. In contrast, SP-B and SP-C are hydrophobic proteins responsible for surfactant adsorption and stabilization at the air-liquid interface[14]. The precise composition of pulmonary surfactants is finely tuned to ensure optimal surfactant function and lung physiology, highlighting the intricate interplay between lipids and proteins in maintaining pulmonary homeostasis.



Figure 2: Therapeutic mechanisms of exogenous pulmonary surfactant.

B. Role of Surfactants in Lung Physiology:

Pulmonary surfactants play a critical role in ensuring the optimal function and integrity of the lungs. Their primary function is to reduce surface tension at the air-liquid interface within the alveoli, thereby preventing alveolar collapse during expiration and facilitating lung compliance[15]. This process, known as adsorption-desorption cycling, allows surfactants to spread across the alveolar surface during inspiration, lowering surface tension and enabling efficient gas exchange[16]. Additionally, surfactants contribute to the stability of the alveoli by preventing alveolar collapse at low lung volumes, thus maintaining the structural integrity of the lung parenchyma. Beyond their mechanical roles, surfactants also participate in lung host defense and immune regulation[17]. Surfactant-associated proteins SP-A and SP-D are involved in innate immune responses, facilitating the clearance of pathogens and particulate matter from the airways and modulating inflammation and immune cell activation. Overall, the multifaceted functions of pulmonary surfactants are essential for maintaining lung physiology and ensuring optimal respiratory function[18].

C. Interaction of Surfactants with Lung Epithelium:

The interplay between pulmonary surfactants and the lung epithelium is a complex and dynamic process that influences various aspects of lung health and function. Upon secretion by type II alveolar epithelial cells, surfactants form a delicate monolayer at the air-liquid interface within the alveoli[19]. This monolayer serves as a crucial barrier, protecting the underlying lung epithelium from mechanical stress and maintaining alveolar stability during the respiratory cycle. Additionally, surfactants play a pivotal role in modulating immune responses and inflammation within the lung[20]. Surfactant-associated proteins, such as SP-A and SP-D, participate in the recognition and clearance of pathogens and particulate matter by interacting with pattern recognition receptors on immune cells and facilitating phagocytosis and clearance mechanisms[21]. Moreover, surfactant proteins SP-B and SP-C are involved in intracellular signaling pathways within alveolar epithelial cells, regulating surfactant production, secretion, and recycling. This intricate interaction between pulmonary surfactants and the lung epithelium underscores their essential role in maintaining pulmonary homeostasis and highlights their potential as therapeutic targets for respiratory diseases and beyond[22].

Challenges in Pulmonary Drug Delivery

Pulmonary drug delivery holds immense promise for the treatment of various respiratory conditions and systemic diseases. However, several challenges must be addressed to ensure the effective delivery of drugs to the lungs.

A. Barriers to Effective Pulmonary Drug Delivery:

1. Mucociliary Clearance: The respiratory tract is lined with a layer of mucus that traps and removes inhaled particles and pathogens through the action of cilia[17]. This mucociliary clearance mechanism poses a significant barrier to the delivery of therapeutics to the lungs, as

it can rapidly clear deposited particles before they can exert their therapeutic effects[23].

2. Epithelial Barrier: The lung epithelium serves as a selective barrier that regulates the passage of molecules into the underlying tissue. Large molecules, such as proteins and nucleic acids, face challenges in crossing this barrier to reach their target sites within the lung parenchyma[24].

3. Enzymatic Degradation: The lungs contain various enzymes, including proteases and nucleases, that can degrade therapeutic molecules, rendering them ineffective before they reach their intended targets[2]. This enzymatic degradation poses a significant challenge for the delivery of biologics and nucleic acid-based therapeutics to the lungs[25].

4. Limited Cellular Uptake: Once delivered to the lungs, therapeutic agents must be taken up by target cells to exert their pharmacological effects. However, the efficiency of cellular uptake can be limited, particularly for large molecules and nanoparticles, reducing the efficacy of pulmonary drug delivery[26].

B. Strategies to Overcome These Barriers:

1. Nanoparticle Formulations: Nanoparticles offer a promising approach to overcome the barriers to pulmonary drug delivery. By encapsulating drugs within nanoparticles, researchers can protect them from enzymatic degradation, prolong their residence time in the lungs, and enhance their cellular uptake. Surface modifications of nanoparticles can also facilitate mucus penetration and evasion of mucociliary clearance[27].

2. Targeted Drug Delivery: Targeting specific cell types or receptors within the lungs can improve the efficacy of pulmonary drug delivery while minimizing off-target effects. Ligand-functionalized nanoparticles can be designed to selectively bind to receptors expressed on target cells, enhancing their uptake and therapeutic effects[28].

3. Inhalation Devices: Advancements in inhalation device technology have enabled precise and controlled delivery of therapeutics to the lungs. Dry powder inhalers (DPIs) and metered-dose inhalers (MDIs) allow for convenient administration of drugs to patients and can be tailored to deliver therapeutics to specific regions of the lung[29].

C. Advantages of Using Pulmonary Surfactants as Drug Delivery Vehicles:

1. Biocompatibility: Pulmonary surfactants are naturally occurring substances produced by the lungs and are therefore inherently biocompatible. When used as drug delivery vehicles, surfactants are less likely to induce adverse immune reactions or tissue damage, making them suitable for pulmonary administration[30].

2. Enhanced Drug Stability: Surfactant-based formulations can protect encapsulated drugs from enzymatic degradation and physical degradation, preserving their stability and bioactivity during storage and upon administration to the lungs[3].

3. Targeted Delivery: Surfactants can be functionalized or modified to target specific cell types or tissues within the lungs, enabling targeted delivery of therapeutics to diseased sites while minimizing systemic exposure and off-target effects[31].

4. Mucoadhesive Properties: Pulmonary surfactants possess mucoadhesive properties, allowing them to adhere to the mucus layer lining the respiratory tract. This mucoadhesion can prolong the residence time of drug-loaded surfactants in the lungs, enhancing drug absorption and efficacy[15].

Endogenous Systems Exploited for Drug Delivery

Pulmonary drug delivery holds immense potential for the treatment of respiratory diseases and systemic conditions. Exploiting endogenous systems within the lung presents an innovative approach to enhance the efficiency and specificity of drug delivery[32].

A. Overview of Endogenous Systems in the Lung:

The lung harbors a myriad of endogenous systems that play crucial roles in maintaining pulmonary homeostasis, immune defense, and tissue repair. These endogenous systems include mucociliary clearance, alveolar macrophages, pulmonary surfactants, and epithelial transport mechanisms. Mucociliary clearance is a primary defense mechanism that clears inhaled particles and pathogens from the airways through the coordinated action of mucus-producing goblet cells and ciliated epithelial cells[33]. Alveolar macrophages are resident immune cells within the alveoli that phagocytose and clear foreign particles and debris, contributing to lung host defense[17]. Pulmonary surfactants, composed of lipids and proteins, reduce surface tension at the air-liquid interface within the alveoli, facilitating respiratory mechanics and maintaining alveolar integrity. Epithelial transport mechanisms, including ion channels and transporters, regulate the movement of ions and solutes across the lung epithelium, maintaining fluid balance and ion homeostasis[34].

B. Mechanisms of Surfactant-Mediated Drug Delivery:

Pulmonary surfactants offer a unique platform for drug delivery due to their ability to interact with lung epithelium and traverse the respiratory tract[2]. The mechanisms of surfactant-mediated drug delivery involve the incorporation of drugs into surfactant formulations, which can then be administered via inhalation or instillation into the lungs[35]. Upon administration, surfactant-drug complexes interact with the lung epithelium, where they can be taken up by alveolar epithelial cells or transported across the epithelial barrier into the systemic circulation. Surfactant-mediated drug delivery exploits endogenous pathways within the lung, including surfactant uptake and recycling mechanisms, to enhance the targeting and bioavailability of therapeutics[36].

C. Examples of Endogenous Pathways Utilized for Drug Delivery:

Several endogenous pathways within the lung have been leveraged for drug delivery, demonstrating the versatility and potential of surfactant-mediated delivery systems[10]. One example is the use of pulmonary surfactants as carriers for inhaled corticosteroids in the treatment of asthma and chronic obstructive pulmonary disease (COPD)[37]. By

encapsulating corticosteroids within surfactant formulations, researchers can enhance drug delivery to inflamed airway tissues, thereby improving therapeutic efficacy and minimizing systemic side effects. Another example is the delivery of therapeutic proteins, such as insulin, via pulmonary surfactants for the treatment of diabetes[38]. Surfactant-mediated delivery of insulin offers a non-invasive alternative to subcutaneous injection, with the potential for improved patient compliance and glycemic control.In addition to surfactant-mediated delivery, other endogenous pathways within the lung, such as epithelial transport mechanisms and alveolar macrophage uptake, have been explored for targeted drug delivery[39]. For instance, inhalable nanoparticles coated with targeting ligands can selectively bind to receptors expressed on lung epithelial cells, facilitating cellular uptake and intracellular drug delivery. Similarly, nanoparticles designed to evade alveolar macrophage clearance can prolong circulation time in the lungs, allowing for sustained drug release and enhanced therapeutic efficacy[40].

Types of Drugs Delivered Using Pulmonary Surfactants

Pulmonary surfactants offer a versatile platform for the delivery of various types of drugs, ranging from small molecule drugs to macromolecular therapeutics and nanoparticles.

A. Small Molecule Drugs:

Small molecule drugs represent a broad category of therapeutics that can be delivered using pulmonary surfactants[41]. These drugs typically have low molecular weights and include bronchodilators, anti-inflammatory agents, antibiotics, and antiviral drugs. Pulmonary surfactants can enhance the delivery of small molecule drugs to the lungs by improving their solubility, stability, and retention in the respiratory tract[30]. For example, surfactant-based formulations have been developed for the delivery of bronchodilators such as albuterol and salmeterol for the treatment of asthma and chronic obstructive pulmonary disease (COPD). By incorporating these drugs into surfactant carriers, researchers can achieve targeted and sustained release in the lungs, leading to improved therapeutic efficacy and reduced systemic side effects[42].

B. Macromolecular Drugs (Proteins, Peptides, Nucleic Acids):

Macromolecular drugs, including proteins, peptides, and nucleic acids, pose unique challenges for pulmonary delivery due to their large size and susceptibility to enzymatic degradation[28]. However, pulmonary surfactants offer a promising platform for the delivery of these therapeutics, as they can protect macromolecules from degradation and facilitate their transport across the lung epithelium[43]. Proteins and peptides, such as insulin and growth factors, have been delivered using surfactant-based formulations for the treatment of diabetes, pulmonary hypertension, and lung injury. Additionally, nucleic acid-based therapeutics, including siRNA and mRNA, have been encapsulated within surfactant carriers for targeted gene delivery to the lungs, offering potential treatments for genetic lung diseases and respiratory infections[44].

C. Lipid-Based Drugs:

Lipid-based drugs, including liposomes, lipid nanoparticles, and lipid-based formulations, are

well-suited for pulmonary delivery using surfactants. Liposomes, composed of phospholipid bilayers, can encapsulate hydrophobic and hydrophilic drugs, providing protection and controlled release in the lungs[45]. Lipid nanoparticles, such as solid lipid nanoparticles (SLNs) and nanostructured lipid carriers (NLCs), offer advantages in terms of stability, biocompatibility, and drug loading capacity. Surfactant-based formulations have been developed for the pulmonary delivery of lipid-based drugs, offering targeted and sustained release in the lungs. These formulations have applications in the treatment of pulmonary infections, cancer, and inflammatory lung diseases[46].

D. Nanoparticles and Microparticles:

Nanoparticles and microparticles represent advanced drug delivery systems that can be delivered to the lungs using surfactants. Nanoparticles, typically in the range of 1-100 nm, offer advantages such as high drug loading capacity, controlled release kinetics, and targeted delivery to specific lung regions[47]. Pulmonary surfactants can enhance the stability, dispersion, and cellular uptake of nanoparticles, facilitating their delivery to the lungs. Examples of nanoparticle-based formulations include polymeric nanoparticles, lipid nanoparticles, and metallic nanoparticles, which have applications in pulmonary drug delivery for the treatment of lung cancer, tuberculosis, and respiratory infections[20]. Microparticles, larger than nanoparticles with sizes ranging from 1 to 1000 μm, can also be delivered using surfactants for sustained release and localized drug delivery in the lungs. These drug delivery systems offer potential applications in the treatment of asthma, cystic fibrosis, and pulmonary hypertension[48].

Methods of Formulating Drug-Surfactant Complexes

Formulating drug-surfactant complexes is a critical step in the development of pulmonary drug delivery systems.

A. Techniques for Incorporating Drugs into Surfactant Formulations:

1. Co-solubilization: One common method for formulating drug-surfactant complexes involves co-solubilization, where drugs and surfactants are dissolved together in a suitable solvent[22]. This method allows for the simultaneous solubilization of hydrophobic drugs within the hydrophobic core of surfactant micelles, enhancing drug stability and bioavailability. Co-solubilization can be achieved using organic solvents, such as ethanol or chloroform, or aqueous solvents, depending on the solubility characteristics of the drug and surfactant[49].

2. Thin Film Hydration: Thin film hydration is another technique commonly used to formulate drug-surfactant complexes, particularly for lipophilic drugs and lipid-based surfactants. In this method, a thin film of surfactant and drug is formed by evaporating a solvent from a mixture of surfactant and drug solution[12]. The film is then hydrated with an aqueous solution to form liposomes or micelles encapsulating the drug. Thin film hydration offers advantages in terms of scalability, reproducibility, and control over particle size and drug loading[50].

3. Co-precipitation: Co-precipitation involves the simultaneous precipitation of drug and surfactant from a solution, resulting in the formation of drug-surfactant complexes[18]. This method is particularly suitable for hydrophobic drugs and surfactants that form insoluble complexes upon mixing. Co-precipitation can be achieved by adding a non-solvent to a solution containing drug and surfactant, leading to the precipitation of drug-surfactant complexes[51].

4. Emulsification: Emulsification is a versatile technique for formulating drug-surfactant complexes, particularly for hydrophobic drugs and surfactants. In this method, a hydrophobic drug is dispersed in an aqueous surfactant solution to form an emulsion[32]. The emulsion is then homogenized or sonicated to reduce droplet size and enhance drug encapsulation within surfactant micelles or liposomes. Emulsification offers advantages in terms of scalability, stability, and control over particle size and drug loading[52].

B. Factors Influencing Drug Loading and Release Kinetics:

Several factors influence the drug loading and release kinetics of drug-surfactant complexes, including the physicochemical properties of the drug and surfactant, formulation parameters, and environmental conditions.

1. Drug Solubility: The solubility of the drug in the surfactant formulation plays a crucial role in drug loading and release kinetics[19]. Hydrophobic drugs tend to partition into the hydrophobic core of surfactant micelles or liposomes, leading to higher drug loading and sustained release kinetics. Conversely, hydrophilic drugs may be encapsulated within the aqueous phase of surfactant formulations, resulting in lower drug loading and faster release kinetics[53].

2. Surfactant Concentration: The concentration of surfactant in the formulation influences drug loading and release kinetics by affecting the size, stability, and structure of surfactant micelles or liposomes[33]. Higher surfactant concentrations generally result in higher drug loading and slower release kinetics, as more drug molecules can be accommodated within the surfactant matrix[54].

3. Formulation Parameters: Formulation parameters, such as pH, temperature, and ionic strength, can impact drug loading and release kinetics by affecting the stability and structure of drug-surfactant complexes. Changes in pH or temperature may alter the solubility of the drug or induce phase transitions within the surfactant formulation, leading to changes in drug release kinetics[22].

4. Environmental Conditions: Environmental conditions, such as humidity, light exposure, and storage temperature, can influence the stability and performance of drug-surfactant complexes. Exposure to harsh environmental conditions may degrade the surfactant or drug molecules, leading to changes in drug loading and release kinetics over time[55].

C. Stability Considerations of Drug-Surfactant Complexes:

Stability considerations are paramount in the formulation of drug-surfactant complexes to ensure the integrity and efficacy of the final product. Several factors must be considered to maintain the stability of drug-surfactant complexes during formulation, storage, and administration[18].

1. Compatibility: Compatibility between the drug and surfactant is essential to prevent drug degradation or physical instability within the formulation. Compatibility studies should be conducted to assess potential interactions between the drug and surfactant molecules and identify any incompatibilities that may affect formulation stability[56].

2. Physical Stability: Physical stability of drug-surfactant complexes refers to their ability to maintain uniformity, particle size, and morphology over time. Physical instability, such as aggregation, precipitation, or phase separation, can compromise the efficacy and safety of the formulation. Formulation techniques should be optimized to minimize physical instability and ensure uniform distribution of drug within the surfactant matrix[57].

3. Chemical Stability: Chemical stability of drug-surfactant complexes refers to their ability to resist chemical degradation, such as hydrolysis, oxidation, or degradation induced by light exposure. Stability-indicating assays should be employed to assess the chemical stability of drug-surfactant complexes under various storage conditions and identify degradation products that may affect drug efficacy and safety[28].

4. Storage Stability: Storage stability of drug-surfactant complexes is crucial to ensure their efficacy and safety during storage and transportation[17]. Formulations should be stored under appropriate conditions, such as controlled temperature and humidity, to prevent degradation and maintain stability over time. Stability testing should be conducted to assess the long-term stability of drug-surfactant complexes and establish shelf-life specifications for commercial products[58].

Table 1: Summary of Surfactant Changes in Chronic Pulmonary Diseases

Pulmonary Disease	**Model**	**Phospholipids**	**Surfactant Proteins**	**Surface Activity**	**References**
Chronic Obstructive Pulmonary Disease (COPD)	In vivo studies in COPD patients	Decreased levels, altered composition	Decreased SP-A and SP-D levels	Reduced surface tension lowering capacity	[15]
Asthma	Animal models, in vitro studies	Altered phospholipid composition	Variable changes in SP-A and SP-D	Variable effects on surface tension	[4]

				lowering capacity	
Cystic Fibrosis	Clinical studies, animal models	Altered composition, increased viscosity	Decreased SP-A and SP-D levels	Impaired surface tension lowering capacity, increased viscosity	[3]
Interstitial Lung Disease (ILD)	Animal models, in vitro studies	Altered phospholipid profile	Variable changes in SP-A and SP-D	Variable effects on surface tension lowering capacity	[7]
Pulmonary Fibrosis	Animal models, in vitro studies	Altered composition, increased cholesterol	Decreased SP-A and SP-D levels	Impaired surface tension lowering capacity, increased stiffness	[33]
Bronchiectasis	Clinical studies, in vitro models	Altered composition	Variable changes in SP-A and SP-D	Variable effects on surface tension lowering capacity	[21]
Pulmonary Alveolar Proteinosis	Clinical studies, animal models	Accumulation of surfactant proteins, decreased phospholipids	Variable changes in SP-A and SP-D	Impaired surfactant function, reduced surface tension lowering capacity	[19]
Pulmonary Hypertension	Animal models, in vitro studies	Variable phospholipid composition	Variable changes in SP-A and SP-D	Variable effects on surface tension lowering capacity	[22]
Idiopathic	Clinical	Altered	Decreased	Impaired	[33]

Pulmonary Fibrosis	studies, animal models	composition, increased cholesterol	SP-A and SP-D levels	surface tension lowering capacity, increased stiffness	
Sarcoidosis	Clinical studies, in vitro models	Altered phospholipid profile	Variable changes in SP-A and SP-D	Variable effects on surface tension lowering capacity	[29]

Applications of Pulmonary Surfactant-Mediated Drug Delivery

Pulmonary surfactant-mediated drug delivery offers a versatile and promising approach for the treatment of various lung diseases, systemic drug delivery via the lungs, targeted delivery to specific lung regions, and the development of imaging and contrast agents[59].

A. Treatment of Lung Diseases:

1. Asthma: Asthma is a chronic inflammatory disorder characterized by airway inflammation, bronchoconstriction, and mucus hypersecretion. Pulmonary surfactant-mediated drug delivery holds potential for the treatment of asthma by delivering bronchodilators, anti-inflammatory agents, and immunomodulators directly to inflamed airway tissues. By encapsulating drugs within surfactant carriers, researchers can achieve targeted and sustained release in the lungs, leading to improved therapeutic efficacy and reduced systemic side effects[60].

2. Chronic Obstructive Pulmonary Disease (COPD): COPD encompasses a group of progressive lung diseases, including chronic bronchitis and emphysema, characterized by airflow limitation and respiratory symptoms. Pulmonary surfactant-mediated drug delivery offers opportunities for the treatment of COPD by delivering bronchodilators, corticosteroids, and mucolytic agents directly to affected lung tissues. By enhancing drug deposition and retention in the lungs, surfactant-based formulations can improve symptom control and lung function in patients with COPD[61].

3. Cystic Fibrosis: Cystic fibrosis is a genetic disorder characterized by abnormal mucus production, chronic airway inflammation, and recurrent respiratory infections. Pulmonary surfactant-mediated drug delivery holds promise for the treatment of cystic fibrosis by delivering antibiotics, mucolytic agents, and gene therapy vectors directly to the lungs. By targeting drugs to the site of infection and inflammation, surfactant-based formulations can enhance therapeutic efficacy and reduce the frequency of exacerbations in patients with cystic fibrosis[62].

B. Systemic Drug Delivery via the Lungs:

Pulmonary surfactant-mediated drug delivery offers a non-invasive route for systemic drug delivery via the lungs, bypassing the gastrointestinal tract and avoiding first-pass metabolism in the liver. This approach is particularly advantageous for drugs with poor oral bioavailability or those that undergo extensive metabolism in the liver. By formulating drugs with surfactant carriers, researchers can achieve rapid absorption and systemic distribution, leading to improved pharmacokinetics and therapeutic outcomes[63].

C. Targeted Delivery to Specific Lung Regions:

Pulmonary surfactant-mediated drug delivery enables targeted delivery to specific lung regions, such as the upper airways, conducting airways, and alveolar regions. This targeted approach allows for the selective deposition of drugs in diseased tissues while minimizing systemic exposure and off-target effects. By modifying surfactant formulations with targeting ligands or nanoparticles, researchers can achieve site-specific delivery of drugs to treat localized lung diseases, such as lung cancer, tuberculosis, and pulmonary fibrosis[64].

D. Imaging Agents and Contrast Agents:
In addition to therapeutic applications, pulmonary surfactant-mediated drug delivery has applications in the development of imaging agents and contrast agents for diagnostic purposes. Surfactant-based formulations can be loaded with imaging agents, such as fluorescent dyes, radiotracers, or magnetic nanoparticles, to enable non-invasive imaging of lung anatomy, physiology, and function. By enhancing the retention and distribution of imaging agents in the lungs, surfactant-mediated delivery systems can improve the sensitivity and specificity of diagnostic imaging techniques, such as positron emission tomography (PET), single-photon emission computed tomography (SPECT), and magnetic resonance imaging (MRI)[65].

Future Perspectives and Emerging Trends
The future of pulmonary drug delivery holds immense promise, driven by advances in surfactant-based drug delivery technologies, novel strategies for enhancing targeting and therapeutic efficacy, potential applications in personalized medicine and precision drug delivery, and regulatory considerations and commercialization prospects[66].

A. Advances in Surfactant-Based Drug Delivery Technologies:

1. Nanotechnology: Nanotechnology holds the potential to revolutionize pulmonary drug delivery by enabling precise control over drug release kinetics, targeting, and bioavailability. Advances in nanoparticle engineering, such as lipid nanoparticles, polymeric nanoparticles, and inorganic nanoparticles, offer opportunities to enhance the stability, solubility, and cellular uptake of drugs delivered using surfactants[67].

2. Engineered Surfactants: Engineered surfactants with tailored physicochemical properties

and functionalities represent a frontier in pulmonary drug delivery. By modifying surfactant compositions, structures, and surface properties, researchers can optimize drug loading, release kinetics, and targeting specificity, leading to enhanced therapeutic outcomes and reduced side effects[68].

3. Inhalation Devices: Innovations in inhalation device technology, such as dry powder inhalers (DPIs), metered-dose inhalers (MDIs), and nebulizers, are poised to improve patient compliance, drug delivery efficiency, and ease of administration. Smart inhalation devices equipped with sensors and feedback mechanisms offer opportunities for personalized dosing and real-time monitoring of patient adherence and treatment response[69].

B. Novel Strategies for Enhancing Targeting and Therapeutic Efficacy:

1. Targeted Delivery Systems: Targeted drug delivery systems, such as ligand-functionalized nanoparticles and antibody-conjugated liposomes, enable precise targeting of diseased tissues and cells within the lungs. By exploiting specific receptors or biomarkers expressed on target cells, these systems enhance drug accumulation and uptake while minimizing off-target effects, leading to improved therapeutic efficacy and safety profiles[70].

2. Combination Therapies: Combination therapies involving multiple drugs or drug classes offer synergistic effects and improved treatment outcomes for complex lung diseases[71]. Pulmonary surfactant-mediated drug delivery provides a platform for co-delivering synergistic drug combinations, such as bronchodilators and anti-inflammatory agents, to achieve additive or synergistic therapeutic effects while reducing the risk of drug resistance and adverse reactions[72].

3. Controlled Release Systems: Controlled release systems, such as stimuli-responsive nanoparticles and microparticles, enable precise control over drug release kinetics and spatiotemporal drug distribution within the lungs[73]. By responding to endogenous or exogenous stimuli, such as pH, temperature, or enzymatic activity, these systems can release drugs in a controlled manner, prolonging drug action and minimizing fluctuations in drug concentration[74].

C. Potential Applications in Personalized Medicine and Precision Drug Delivery:

1. Biomarker-Based Therapeutics: Advances in biomarker discovery and personalized medicine enable the development of biomarker-based therapeutics tailored to individual patient profiles and disease characteristics[75]. Pulmonary surfactant-mediated drug delivery offers opportunities for precision drug delivery based on patient-specific biomarkers, genetic polymorphisms, and disease phenotypes, leading to personalized treatment regimens and optimized therapeutic outcomes[76].

2. Pharmacogenomics: Pharmacogenomic approaches leverage genetic information to predict individual patient responses to drugs and optimize treatment strategies accordingly. Pulmonary drug delivery systems can be tailored to deliver genotype-specific therapeutics,

adjust drug dosing based on genetic variations in drug metabolism or transport, and minimize interindividual variability in drug response and toxicity[77].

3. Disease Modeling and Drug Screening: Patient-derived lung organoids and in vitro disease models provide platforms for disease modeling, drug screening, and personalized drug testing. Pulmonary surfactant-mediated drug delivery systems can be integrated into these models to evaluate drug efficacy, toxicity, and pharmacokinetics in a patient-specific context, guiding personalized treatment decisions and drug development strategies[78].

D. Regulatory Considerations and Commercialization Prospects:

1. Regulatory Pathways: The regulatory landscape for pulmonary drug delivery is evolving to accommodate advances in drug delivery technologies and personalized medicine approaches. Regulatory agencies, such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), are developing guidelines and frameworks for the evaluation and approval of novel drug delivery systems, biomarker-based therapeutics, and personalized medicine approaches[79].

2. Commercialization Opportunities: Pulmonary drug delivery technologies represent a burgeoning market with significant commercialization opportunities for pharmaceutical companies, biotechnology startups, and academic research institutions[80]. Investments in research and development, intellectual property protection, and strategic partnerships are essential for translating innovative drug delivery technologies into commercial products and addressing unmet medical needs in respiratory diseases and beyond[81].

Conclusion

Pulmonary surfactant-mediated drug delivery holds tremendous potential for revolutionizing the treatment of respiratory diseases and advancing personalized medicine. The diverse applications of surfactant-based drug delivery technologies, including targeted delivery to specific lung regions, systemic drug delivery via the lungs, and the development of imaging and contrast agents, offer opportunities to improve therapeutic outcomes, minimize side effects, and enhance patient compliance. Emerging trends such as nanotechnology, engineered surfactants, and biomarker-based therapeutics are poised to drive innovation in pulmonary drug delivery, enabling precise control over drug release kinetics, targeting specificity, and therapeutic efficacy. Moreover, regulatory considerations and commercialization prospects underscore the growing interest and investment in pulmonary drug delivery technologies, paving the way for the translation of research advancements into clinical applications and commercial products. As the field continues to evolve, collaborations between researchers, clinicians, industry stakeholders, and regulatory agencies will be crucial for advancing pulmonary drug delivery technologies, addressing unmet medical needs, and improving patient care in respiratory diseases and beyond. By harnessing the potential of pulmonary surfactant-mediated drug delivery, we can usher in a new era of precision medicine and personalized therapeutics tailored to individual patient profiles and disease characteristics, ultimately improving health outcomes and quality of life for patients

worldwide.

References

1. M. Videira, A. N. J. Almeida, and A. N. Fabra, "Preclinical evaluation of a pulmonary delivered paclitaxel-loaded lipid nanocarrier antitumor effect," Nanomedicine, vol. 8, pp. 1208–1215, 2012.

2. N. V. Koshkina et al., "Paclitaxel liposome aerosol treatment induces inhibition of pulmonary metastases in murine renal carcinoma model," Clin Cancer Res, vol. 7, pp. 3258–3262, 2001.

3. N. V. Koshkina et al., "Distribution of camptothecin after delivery as a liposome aerosol or following intramuscular injection in mice," Cancer Chemother Pharmacol, vol. 44, pp. 187–192.

4. C.-L. Tseng et al., "Development of gelatin nanoparticles with biotinylated EGF conjugation for lung cancer targeting," Biomaterials, vol. 28, pp. 3996–4005, 2007.

5. N. K. Verma et al., "Magnetic core-shell nanoparticles for drug delivery by nebulization," J Nanobiotechnology, vol. 11, pp. 1.

6. J. W. Card et al., "Pulmonary applications and toxicity of engineered nanoparticles," Am J Physiol Lung Cell Mol Physiol, vol. 295, pp. L400–L411, 2008.

7. J. J. Li et al., "Nanoparticle-induced pulmonary toxicity," Exp Biol Med, vol. 235, pp. 1025–1033, 2010.

8. J. G. Li et al., "The pulmonary toxicity of multi-wall carbon nanotubes in mice 30 and 60 days after inhalation exposure," J Nanosci Nanotechnol, vol. 9, pp. 1384–1387, 2009.

9. J. McCarthy et al., "Mechanisms of toxicity of amorphous silica nanoparticles on human lung submucosal cells in vitro: protective effects of fisetin," Chem Res Toxicol, vol. 25, pp. 2227–2235, 2012.

10. L. A. Dailey et al., "Investigation of the proinflammatory potential of biodegradable nanoparticle drug delivery systems in the lung," Toxicol Appl Pharmacol, vol. 215, pp. 100–108, 2006.

11. S. Dokka et al., "Oxygen radical-mediated pulmonary toxicity induced by some cationic liposomes," Pharm Res, vol. 17, pp. 521–525.

12. K. Donaldson et al., "Identifying the pulmonary hazard of high aspect ratio

nanoparticles to enable their safety-by-design," Nanomedicine, vol. 6, pp. 143–156, 2010.

13. Y.-H. Park et al., "Effect of the size and surface charge of silica nanoparticles on cutaneous toxicity," Mol Cell Toxicol, vol. 9, pp. 67–74, 2013.

14. A. B. Fisher et al., "Altered lung phospholipid metabolism in mice with targeted deletion of lysosomal-type phospholipase A2," J Lipid Res, vol. 46, pp. 1248–1256, 2005.

A. S. Kaviratna and R. Banerjee, "Nanovesicle aerosols as surfactant therapy in lung injury," Nanomedicine, vol. 8, pp. 665–672, 2012.

15. J. Perez-Gil, "Structure of pulmonary surfactant membranes and films: the role of proteins and lipid-protein interactions," Biochim Biophys Acta, vol. 1778, pp. 1676–1695, 2008.

16. V. Schram and S. B. Hall, "Thermodynamic effects of the hydrophobic surfactant proteins on the early adsorption of pulmonary surfactant," Biophys J, vol. 81, pp. 1536–1546, 2001.

I. M. Hafez and P. R. Cullis, "Roles of lipid polymorphism in intracellular delivery," Adv Drug Delivery Rev, vol. 47, pp. 139–148, 2001.

17. G. Cevc and H. Richardsen, "Lipid vesicles and membrane fusion," Adv Drug Delivery Rev, vol. 38, pp. 207–232, 1999.

18. T. L. Andresen, S. S. Jensen, and K. et al., "Advanced strategies in liposomal cancer therapy: Problems and prospects of active and tumor specific drug release," Prog Lipid Res, vol. 44, pp. 68–97, 2005.

19. N. Joshi et al., "Proapoptotic lipid nanovesicles: Synergism with paclitaxel in human lung adenocarcinoma A549 cells," J Controlled Release, vol. 156, pp. 413–420, 2011.

20. D. Bangham, M. M. Standish, and J. C. Watkins, "Diffusion of univalent ions across the lamellae of swollen phospholipids," J Mol Biol, vol. 13, pp. 238–252, 1965.

21. S. M. Van Schaik et al., "Surfactant dysfunction develops in BALB/c mice infected with respiratory syncytial virus," Pediatr Res, vol. 42, pp. 169–173, 1997.

22. G. Chimote and R. Banerjee, "Evaluation of antitubercular drug-loaded surfactants as inhalable drug-delivery systems for pulmonary tuberculosis," J Biomed Mater Res, Part A, vol. 89, pp. 281–292, 2009.

23. G. W. Hallworth and D. G. Westmoreland, "The twin impinger: a simple device for assessing the delivery of drugs from metered dose pressurized aerosol inhalers," J Pharm Pharmacol, vol. 39, pp. 966–972, 1987.

24. Dijkstra et al., "Incorporation of LPS in liposomes diminishes its ability to induce tumoricidal activity and tumor necrosis factor secretion in murine macrophages," J Leukocyte Biol, vol. 43, pp. 436–444, 1988.

25. J. O. Sham et al., "Formulation and characterization of spray-dried powders containing nanoparticles for aerosol delivery to the lung," Int J Pharm, vol. 269, pp. 457–467, 2004.

26. R. Knowles and R. C. Boucher, "Mucus clearance as a primary innate defense mechanism for mammalian airways," J Clin Invest, vol. 109, pp. 571–577, 2002.

27. D. A. Edwards et al., "Large Porous Particles for Pulmonary Drug Delivery," Science, vol. 276, pp. 1868–1872, 1997.

28. J. Zhu et al., "Size-dependent cellular uptake efficiency, mechanism and cytotoxicity of silica nanoparticles toward HeLa cells," Talanta, vol. 107, pp. 408–415, 2013.

29. J. A. Zasadzinski et al., "Inhibition of pulmonary surfactant adsorption by serum and the mechanisms of reversal by hydrophilic polymers: Theory," Biophys J, vol. 89, pp. 1621–1629, 2005.

30. A. Holm, Z. Wang, and R. H. Notter, "Multiple mechanisms of lung surfactant inhibition," Pediatr Res, vol. 46, pp. 85–93, 1999.

31. J. G. C. Araujo et al., "Biodistribution and antitumoral effect of long-circulating and pH-sensitive liposomal cisplatin administered in Ehrlich tumor-bearing mice," Exp Biol Med (Maywood), vol. 236, pp. 808–815, 2011.

32. T. Ishida et al., "Development of pH-sensitive liposomes that efficiently retain encapsulated doxorubicin (DXR) in blood," Int J Pharm, vol. 309, pp. 94–100, 2006.

33. Chen et al., "pH and temperature dual-sensitive liposome gel based on novel cleavable mPEG-Hz-CHEMS polymeric vaginal delivery system," Int J Nanomedicine, vol. 7, pp. 2621–2630, 2012.
34. P. Bhatt et al., "Artificial intelligence in pharmaceutical industry: Revolutionizing drug development and delivery," The Chinese Journal of Artificial Intelligence, 2023.

35. P. Bhatt et al., "Blockchain technology applications for improving quality of electronic healthcare system," in Blockchain for Healthcare Systems, 2021, pp. 97–113.

36. P. Bhatt, "Mouth Dissolving Tablets Challenges, Preparation Strategies with a Special Emphasis on Losartan Potassium–A Review," World J. Pharm. Pharm. Sci, vol. 7, no. 9, pp. 271-287, 2018.

37. J. S. Beckman et al., "Superoxide dismutase and catalase conjugated to polyethylene glycol increases endothelial enzyme activity and oxidant resistance," J Biol Chem, vol. 263, pp. 6884–6892, 1988.

38. S. Mishra et al., "Poly(alkylene oxide) copolymers for nucleic acid delivery," Acc Chem Res, vol. 45, pp. 1057–1066, 2012.

39. V. Koshkina et al., "Improved respiratory delivery of the anticancer drugs, camptothecin and paclitaxel, with 5% CO2-enriched air: pharmacokinetic studies," Cancer Chemother Pharmacol, vol. 47, pp. 451–456, 2001.

40. J. Ferreira, J. Cemlyn-Jones, and C. Robalo Cordeiro, "Nanoparticles, nanotechnology and pulmonary nanotoxicology," Rev Port Pneumol, vol. 19, pp. 28–37, 2013.

41. Egerdie and M. Singer, "Morphology of gel state phosphatidylethanolamine and phosphatidylcholine liposomes: a negative stain electron microscopic study," Chem Phys Lipids, vol. 31, pp. 75–85, 1982.
42. S. Ahamed, P. Bhatt, S. J. Sultanuddin, R. Walia, M. A. Haque, and S. B. InayathAhamed, "An Intelligent IoT enabled Health Care Surveillance using Machine Learning," in 2022 International Conference on Advances in Computing, Communication and Applied Informatics (ACCAI). IEEE, 2022.

43. V. Ahmed, S. Sharma, and P. Bhatt, "Formulation and evaluation of sustained release tablet of diltiazem hydrochloride," International Journal of Pharmaceutical Sciences and Research, vol. 11, no. 5, pp. 2193–2198, 2020.

44. A. E. Al-Snafi, S. Singh, P. Bhatt, and V. Kumar, "A review on prescription and non-prescription appetite suppressants and evidence-based method to treat overweight and obesity," GSC biol pharm sci, vol. 19, no. 3, pp. 148–155, 2022.

45. B. Baskar, S. Ramakrishna, and A. Daniela La Rosa, Eds., Encyclopedia of green materials. Singapore: Springer Nature Singapore, 2022.

46. P. Bhatt et al., "Nanorobots recent and future advances in cancer or dentistry therapy-A review," Am J PharmTech Res, vol. 9, no. 3, pp. 321–331, 2019.

47. P. Bhatt et al., "Citrus Flavonoids: Recent Advances and Future Perspectives On Preventing Cardiovascular Diseases," in The Flavonoids, 2024, pp. 131-152.

48. P. Bhatt et al., "Functional and tableting properties of alkali-isolated and phosphorylated barnyard millet (Echinochloa esculenta) starch," ACS Omega, vol. 8, no. 33, pp. 30294–305, 2023.

49. P. Bhatt et al., "Plasma modification techniques for natural polymer-based drug delivery systems," Pharmaceutics, vol. 15, no. 8, p. 2066, 2023.

50. P. Bhatt et al., "Comparative study and in vitro evaluation of sustained release marketed formulation of aceclofenac sustained release tablets," Pharma Science Monitor, vol. 9, no. 2, 2018.

51. P. Bhatt et al., "Development and characterization of fast dissolving buccal strip of frovatriptan succinate monohydrate for buccal delivery," Int J Pharm Investig, vol. 11, no. 1, pp. 69–75, 2021.

B. Goyal et al., "Estimation of shelf-life of Balachaturbhadrika syrup containing different sweetening agents," Res J Pharm Technol, pp. 5078–5083, 2022.

52. T. Kaur and S. Singh, "Controlled release of bi-layered malvidin tablets using 3D printing techniques," J Pharm Res Int, pp. 70–78, 2021.
53. M. Kaurav et al., "In-depth analysis of the chemical composition, pharmacological effects, pharmacokinetics, and patent history of mangiferin," Phytomed Plus, vol. 3, no. 2, p. 100445, 2023.
54. A. Kumar, P. Bhatt, and N. Mishra, "Irritable bowel Syndrome with reference of Alosetron Hydrochloride and Excipient profile used in the manufacturing of Alosetron tablet-A review," J Chem Pharm Sci, vol. 12, no. 03, pp. 71–78, 2019.

55. M. K. Malik et al., "Significance of chemically derivatized starch as drug carrier in developing novel drug delivery devices," Nat Prod J, 2022.

56. M. K. Malik et al., "Preclinical safety assessment of chemically cross-linked modified mandua starch: Acute and sub-acute oral toxicity studies in Swiss albino mice," ACS Omega, vol. 7, no. 40, pp. 35506–35514, 2022.

57. M. K. Malik et al., "Phosphorylation of alkali extracted mandua starch by STPP/STMP for improving digestion resistibility," ACS Omega, vol. 8, no. 13, pp. 11750–11767, 2023.

58. Pankaj, "Anti-cancer cyclodextrin nanocapsules based formulation development for lung chemotherapy," J Pharm Res Int, pp. 54–63, 2021.

59. Pankaj, "Cyclodextrin modified block polymer for oral chemotherapy," J Pharm Res Int, pp. 21–29, 2021.

60. V. Raghuwanshi et al., "Recent Advances In Nanotechnology For Combating Against Corona Virus Infection," Journal of Pharmaceutical Negative Results, pp. 1811-1820, 2022.

61. K. K. Sahu et al., "Utility of nanomaterials in wound management," in Nanotechnological Aspects for Next-Generation Wound Management, 2024, pp. 101–130.

62. S. K. Sharma et al., "Combined therapy with ivermectin and doxycycline can effectively alleviate the cytokine storm of COVID-19 infection amid vaccination drive: A narrative review," J Infect Public Health, vol. 15, no. 5, pp. 566–572, 2022.

63. S. K. Sharma and P. Bhatt, "Controlled release of bi-layered EGCG tablets using 3D printing techniques," J Pharm Res Int, pp. 5–13, 2021.

64. S. K. Sharma and S. Singh, "Antimicrobial Herbal Soap Formulation," Journal of Pharmaceutical Research International, vol. 32, no. 36, pp. 82-88, 2022.

65. S. Singh et al., "Cardiovascular comorbidity of COVID-19 disease: A review," WJPMR, vol. 8, no. 4, pp. 216–225, 2022.

66. S. Singh et al., "Phytonutrients, Anthocyanidins, and Anthocyanins: Dietary and Medicinal Pigments with Possible Health Benefits," in Advances in Flavonoids for Human Health and Prevention of Diseases, 2024, pp. 23-46.

67. S. Singh et al., "Digital Transformation in Healthcare: Innovation and Technologies," in Blockchain for Healthcare Systems, 2021, pp. 61–79.

68. S. Singh et al., "Alginate based Nanoparticles and Its Application in Drug Delivery Systems," Journal of Pharmaceutical Negative Results, pp. 1463-1469, 2022.

69. R. Johari et al., "Artificial Intelligence and Machine Learning in Drug Discovery and Development," in 2023 12th International Conference on System Modeling & Advancement in Research Trends (SMART), 2023, pp. 556-561.’

70. O. Nornoo and D. S.-L. Chow, "Cremophor-free intravenous microemulsions for paclitaxel: II. Stability, in vitro release and pharmacokinetics," Int J Pharm, vol. 349, pp. 117–123, 2008.

71. L. Caseli et al., "Interaction of oligonucleotide-based amphiphilic block copolymers with cell membrane models," J Colloid Interface Sci, vol. 347, pp. 56–61, 2010.
72. Here are the references formatted in IEEE style:

73. L. Xu, Y. Yang, and Y. Y. Zuo, "Atomic force microscopy imaging of adsorbed

pulmonary surfactant films," Biophys. J., vol. 119, pp. 756–766, 2020. [Online]. Available: https://doi.org/10.1016/j.bpj.2020.06.033

74. Schürch, O. L. Ospina, A. Cruz, and J. Pérez-Gil, "Combined and independent action of proteins SP-B and SP-C in the surface behavior and mechanical stability of pulmonary surfactant films," Biophys. J., vol. 99, pp. 3290–3299, 2010. [Online]. Available: https://doi.org/10.1016/j.bpj.2010.09.039

75. G. Serrano and J. Pérez-Gil, "Protein–lipid interactions and surface activity in the pulmonary surfactant system," Chem. Phys. Lipids, vol. 141, pp. 105–118, 2006. [Online]. Available: https://doi.org/10.1016/j.chemphyslip.2006.02.017

76. J. Goerke, "Pulmonary surfactant: Functions and molecular composition," Biochim. Biophys. Acta Mol. Basis Dis., vol. 1408, pp. 79–89, 1998. [Online]. Available: https://doi.org/10.1016/S0925-4439(98)00060-X

77. Lopez-Rodriguez and J. Pérez-Gil, "Structure-function relationships in pulmonary surfactant membranes: From biophysics to therapy," Biochim. Biophys. Acta Biomembr., vol. 1838, pp. 1568–1585, 2014. [Online]. Available: https://doi.org/10.1016/j.bbamem.2014.01.028

78. Y. Y. Zuo et al., "Current perspectives in pulmonary surfactant—Inhibition, enhancement and evaluation," Biochim. Biophys. Acta Biomembr., vol. 1778, pp. 1947–1977, 2008. [Online]. Available: https://doi.org/10.1016/j.bbamem.2008.03.021

79. J. Pérez-Gil and T. E. Weaver, "Pulmonary surfactant pathophysiology: Current models and open questions," Physiology, vol. 25, pp. 132–141, 2010. [Online]. Available: https://doi.org/10.1152/physiol.00006.2010

80. B. Baer et al., "Exogenous surfactant as a pulmonary delivery vehicle for budesonide in vivo," Lung, vol. 198, pp. 909–916, 2020. [Online]. Available: https://doi.org/10.1007/s00408-020-00399-2

81. B. J. Banaschewski et al., "Antimicrobial and biophysical properties of surfactant supplemented with an antimicrobial peptide for treatment of bacterial pneumonia," Antimicrob. Agents Chemother., vol. 59, pp. 3075–3083, 2015. [Online]. Available: https://doi.org/10.1128/AAC.04937-14